Phenergan and Potassium phosphate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Phenergan (promethazine hydrochloride) and Potassium phosphate (potassium). Common drug interactions include acute myeloid leukaemia among females and acetabulum fracture among males.

The phase IV clinical study analyzes what interactions people have when they take Phenergan and Potassium phosphate. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.

What is Potassium phosphate?

Potassium phosphate has active ingredients of potassium. eHealthMe is studying from 578 Potassium phosphate users. Check the latest studies of Potassium phosphate.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 29, 2026

19 people who take Phenergan and Potassium phosphate together, and have interactions are studied.

Phenergan and Potassium phosphate drug interactions.

What are the common drug interactions of Phenergan and Potassium Phosphate, by gender? *:

female:

  1. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  2. Death
  3. Pneumonia
  4. Urinary tract infection
  5. Fungal sepsis (whole body infection by fungus)
  6. Abasia (inability to walk)
  7. Abdominal abscess (collection of pus in abdomen)
  8. Abdominal distension
  9. Abdominal pain upper
  10. Acute leukaemia (blood cancer)

male:

  1. Acetabulum fracture (socket of the hip joint- fracture)
  2. Lung neoplasm (tumour of lung)
  3. Colon cancer stage iv
  4. Anaemia (lack of blood)
  5. Electrolyte imbalance
  6. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
  7. Scrotal abscess (pus in scrotum)
  8. Sepsis (a severe blood infection that can lead to organ failure and death)

What are the common drug interactions of Phenergan and Potassium Phosphate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Abasia (inability to walk)
  2. Abdominal abscess (collection of pus in abdomen)
  3. Acute leukaemia (blood cancer)
  4. Arthralgia (joint pain)
  5. Confusional state
  6. Emotional distress
  7. Myalgia (muscle pain)
  8. Pain in extremity
  9. Panic disorder
  10. Pneumonia

30-39:

n/a

40-49:

  1. Colon cancer stage iv
  2. Abdominal distension
  3. Abdominal pain upper
  4. Acute respiratory distress syndrome
  5. Ascites (accumulation of fluid in the abdominal cavity)
  6. Dyspnoea (difficult or laboured respiration)
  7. Fatigue (feeling of tiredness)
  8. Hypophagia (reduced food intake)
  9. Ischaemic gastritis (inflammation of the lining of the stomach due to inadequate supply of blood)
  10. Multi-organ failure (multisystem organ failure)

50-59:

  1. Fungal sepsis (whole body infection by fungus)
  2. Acetabulum fracture (socket of the hip joint- fracture)
  3. Lung neoplasm (tumour of lung)

60+:

  1. Haemorrhage intracranial (bleeding within the skull)
  2. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  3. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  4. Death
  5. Urinary tract infection
  6. Anaemia (lack of blood)
  7. Electrolyte imbalance
  8. Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

  1. Pain: 9 people, 47.37%
  2. Constipation: 8 people, 42.11%
  3. Diarrhea: 5 people, 26.32%
  4. Multiple Myeloma (cancer of the plasma cells): 5 people, 26.32%
  5. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 4 people, 21.05%
  6. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 15.79%
  7. Stress And Anxiety: 3 people, 15.79%
  8. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 15.79%
  9. Anaemia (lack of blood): 3 people, 15.79%
  10. Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 15.79%

* Approximation only. Some reports may have incomplete information.

Do you take Phenergan and Potassium phosphate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Phenergan and Potassium phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Potassium phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Phenergan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Potassium phosphate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on promethazine hydrochloride and potassium (the active ingredients of Phenergan and Potassium phosphate, respectively), and Phenergan and Potassium phosphate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: